303 related articles for article (PubMed ID: 28030815)
1. A novel non-canonical Wnt signature for prostate cancer aggressiveness.
Sandsmark E; Hansen AF; Selnæs KM; Bertilsson H; Bofin AM; Wright AJ; Viset T; Richardsen E; Drabløs F; Bathen TF; Tessem MB; Rye MB
Oncotarget; 2017 Feb; 8(6):9572-9586. PubMed ID: 28030815
[TBL] [Abstract][Full Text] [Related]
2. Patient-Level DNA Damage and Repair Pathway Profiles and Prognosis After Prostatectomy for High-Risk Prostate Cancer.
Evans JR; Zhao SG; Chang SL; Tomlins SA; Erho N; Sboner A; Schiewer MJ; Spratt DE; Kothari V; Klein EA; Den RB; Dicker AP; Karnes RJ; Yu X; Nguyen PL; Rubin MA; de Bono J; Knudsen KE; Davicioni E; Feng FY
JAMA Oncol; 2016 Apr; 2(4):471-80. PubMed ID: 26746117
[TBL] [Abstract][Full Text] [Related]
3. Abi1 loss drives prostate tumorigenesis through activation of EMT and non-canonical WNT signaling.
Nath D; Li X; Mondragon C; Post D; Chen M; White JR; Hryniewicz-Jankowska A; Caza T; Kuznetsov VA; Hehnly H; Jamaspishvili T; Berman DM; Zhang F; Kung SHY; Fazli L; Gleave ME; Bratslavsky G; Pandolfi PP; Kotula L
Cell Commun Signal; 2019 Sep; 17(1):120. PubMed ID: 31530281
[TBL] [Abstract][Full Text] [Related]
4. Gene expression signature of Gleason score is associated with prostate cancer outcomes in a radical prostatectomy cohort.
Jhun MA; Geybels MS; Wright JL; Kolb S; April C; Bibikova M; Ostrander EA; Fan JB; Feng Z; Stanford JL
Oncotarget; 2017 Jun; 8(26):43035-43047. PubMed ID: 28496006
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic signature of Gleason score and prostate cancer recurrence after radical prostatectomy.
Geybels MS; Wright JL; Bibikova M; Klotzle B; Fan JB; Zhao S; Feng Z; Ostrander EA; Lin DW; Nelson PS; Stanford JL
Clin Epigenetics; 2016; 8():97. PubMed ID: 27651837
[TBL] [Abstract][Full Text] [Related]
6. Molecular Subgroup of Primary Prostate Cancer Presenting with Metastatic Biology.
Walker SM; Knight LA; McCavigan AM; Logan GE; Berge V; Sherif A; Pandha H; Warren AY; Davidson C; Uprichard A; Blayney JK; Price B; Jellema GL; Steele CJ; Svindland A; McDade SS; Eden CG; Foster C; Mills IG; Neal DE; Mason MD; Kay EW; Waugh DJ; Harkin DP; Watson RW; Clarke NW; Kennedy RD
Eur Urol; 2017 Oct; 72(4):509-518. PubMed ID: 28408174
[TBL] [Abstract][Full Text] [Related]
7. Wnt5a signaling is involved in the aggressiveness of prostate cancer and expression of metalloproteinase.
Yamamoto H; Oue N; Sato A; Hasegawa Y; Yamamoto H; Matsubara A; Yasui W; Kikuchi A
Oncogene; 2010 Apr; 29(14):2036-46. PubMed ID: 20101234
[TBL] [Abstract][Full Text] [Related]
8. Integration of tissue metabolomics, transcriptomics and immunohistochemistry reveals ERG- and gleason score-specific metabolomic alterations in prostate cancer.
Meller S; Meyer HA; Bethan B; Dietrich D; Maldonado SG; Lein M; Montani M; Reszka R; Schatz P; Peter E; Stephan C; Jung K; Kamlage B; Kristiansen G
Oncotarget; 2016 Jan; 7(2):1421-38. PubMed ID: 26623558
[TBL] [Abstract][Full Text] [Related]
9. A TMEFF2-regulated cell cycle derived gene signature is prognostic of recurrence risk in prostate cancer.
Georgescu C; Corbin JM; Thibivilliers S; Webb ZD; Zhao YD; Koster J; Fung KM; Asch AS; Wren JD; Ruiz-Echevarría MJ
BMC Cancer; 2019 May; 19(1):423. PubMed ID: 31060542
[TBL] [Abstract][Full Text] [Related]
10. Quercetin modulates Wnt signaling components in prostate cancer cell line by inhibiting cell viability, migration, and metastases.
Baruah MM; Khandwekar AP; Sharma N
Tumour Biol; 2016 Oct; 37(10):14025-14034. PubMed ID: 27495232
[TBL] [Abstract][Full Text] [Related]
11. A Cumulative Analysis of Current Evidence for Association between Expression of Epithelial-Mesenchymal Transition Markers and Clinicopathological Outcomes in Patients after Radical Prostatectomy.
Jiang G; Hu Q; Wang H; Ding W; Zhang N; Wu Y; Zhou Q; Sun C; Xia G; Ding Q; Na R; Xu K
Ann Clin Lab Sci; 2018 Jan; 48(1):18-28. PubMed ID: 29530992
[TBL] [Abstract][Full Text] [Related]
12. Presence of TMPRSS2-ERG is associated with alterations of the metabolic profile in human prostate cancer.
Hansen AF; Sandsmark E; Rye MB; Wright AJ; Bertilsson H; Richardsen E; Viset T; Bofin AM; Angelsen A; Selnæs KM; Bathen TF; Tessem MB
Oncotarget; 2016 Jul; 7(27):42071-42085. PubMed ID: 27276682
[TBL] [Abstract][Full Text] [Related]
13. Gene expression in normal-appearing tissue adjacent to prostate cancers are predictive of clinical outcome: evidence for a biologically meaningful field effect.
Magi-Galluzzi C; Maddala T; Falzarano SM; Cherbavaz DB; Zhang N; Knezevic D; Febbo PG; Lee M; Lawrence HJ; Klein EA
Oncotarget; 2016 Jun; 7(23):33855-65. PubMed ID: 27121323
[TBL] [Abstract][Full Text] [Related]
14. Markers of epithelial-to-mesenchymal transition reflect tumor biology according to patient age and Gleason score in prostate cancer.
Jędroszka D; Orzechowska M; Hamouz R; Górniak K; Bednarek AK
PLoS One; 2017; 12(12):e0188842. PubMed ID: 29206234
[TBL] [Abstract][Full Text] [Related]
15. Clinical significance of epithelial-mesenchymal transition markers in prostate cancer.
Figiel S; Vasseur C; Bruyere F; Rozet F; Maheo K; Fromont G
Hum Pathol; 2017 Mar; 61():26-32. PubMed ID: 27818287
[TBL] [Abstract][Full Text] [Related]
16. A Prostate Cancer "Nimbosus": Genomic Instability and SChLAP1 Dysregulation Underpin Aggression of Intraductal and Cribriform Subpathologies.
Chua MLK; Lo W; Pintilie M; Murgic J; Lalonde E; Bhandari V; Mahamud O; Gopalan A; Kweldam CF; van Leenders GJLH; Verhoef EI; Hoogland AM; Livingstone J; Berlin A; Dal Pra A; Meng A; Zhang J; Orain M; Picard V; Hovington H; Bergeron A; Lacombe L; Fradet Y; Têtu B; Reuter VE; Fleshner N; Fraser M; Boutros PC; van der Kwast TH; Bristow RG
Eur Urol; 2017 Nov; 72(5):665-674. PubMed ID: 28511883
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive study of gene and microRNA expression related to epithelial-mesenchymal transition in prostate cancer.
Katz B; Reis ST; Viana NI; Morais DR; Moura CM; Dip N; Silva IA; Iscaife A; Srougi M; Leite KR
PLoS One; 2014; 9(11):e113700. PubMed ID: 25409297
[TBL] [Abstract][Full Text] [Related]
18. Berberine inhibits the metastatic ability of prostate cancer cells by suppressing epithelial-to-mesenchymal transition (EMT)-associated genes with predictive and prognostic relevance.
Liu CH; Tang WC; Sia P; Huang CC; Yang PM; Wu MH; Lai IL; Lee KH
Int J Med Sci; 2015; 12(1):63-71. PubMed ID: 25552920
[TBL] [Abstract][Full Text] [Related]
19. Glycidamide Promotes the Growth and Migratory Ability of Prostate Cancer Cells by Changing the Protein Expression of Cell Cycle Regulators and Epithelial-to-Mesenchymal Transition (EMT)-Associated Proteins with Prognostic Relevance.
Ekanem TI; Huang CC; Wu MH; Lin DY; Lai WT; Lee KH
Int J Mol Sci; 2019 May; 20(9):. PubMed ID: 31060254
[TBL] [Abstract][Full Text] [Related]
20. Nuclear factor-kappaB-mediated transforming growth factor-beta-induced expression of vimentin is an independent predictor of biochemical recurrence after radical prostatectomy.
Zhang Q; Helfand BT; Jang TL; Zhu LJ; Chen L; Yang XJ; Kozlowski J; Smith N; Kundu SD; Yang G; Raji AA; Javonovic B; Pins M; Lindholm P; Guo Y; Catalona WJ; Lee C
Clin Cancer Res; 2009 May; 15(10):3557-67. PubMed ID: 19447876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
